Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

Summary

Single-arm, open-label, single-center study to evaluate the efficacy and safety of baricitinib for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

Timeline

Start

2022-07-13

Primary completion

2023-06-01

Completion

2023-12-01

Publications

• Zhao P, An ZY, Fu HX, Liu HX, Feng CJ, Huang QS, Wu J, Wu YJ, Yang LP, Qu QY, Chen YX, Li ML, Wang CC, Chen Q, Zhu XL, He Y, Zhang YY, Jiang Q, Jiang H, Lu J, Chang YJ, Zhao XS, Zhao XY, Huang XJ, Zhang XH. Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: An open-label pilot study. Am J Hematol. 2024 Oct;99(10):1951-1958. doi: 10.1002/ajh.27433. Epub 2024 Jul 9.

Drugs

Indications